Cargando…
Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo
The failure of cytotoxic chemotherapy in breast cancers has been closely associated with the presence of drug resistant cancer stem cells (CSCs). Thus, screening for small molecules that selectively inhibit growth of CSCs may offer great promise for cancer control, particularly in combination with c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808032/ https://www.ncbi.nlm.nih.gov/pubmed/26506421 |
_version_ | 1782423463609237504 |
---|---|
author | Jia, Deyong Tan, Yuan Liu, Huijuan Ooi, Sarah Li, Li Wright, Kathryn Bennett, Steffany Addison, Christina L. Wang, Lisheng |
author_facet | Jia, Deyong Tan, Yuan Liu, Huijuan Ooi, Sarah Li, Li Wright, Kathryn Bennett, Steffany Addison, Christina L. Wang, Lisheng |
author_sort | Jia, Deyong |
collection | PubMed |
description | The failure of cytotoxic chemotherapy in breast cancers has been closely associated with the presence of drug resistant cancer stem cells (CSCs). Thus, screening for small molecules that selectively inhibit growth of CSCs may offer great promise for cancer control, particularly in combination with chemotherapy. In this report, we provide the first demonstration that cardamonin, a small molecule, selectively inhibits breast CSCs that have been enriched by chemotherapeutic drugs. In addition, cardamonin also sufficiently prevents the enrichment of CSCs when simultaneously used with chemotherapeutic drugs. Specifically, cardamonin effectively abolishes chemotherapeutic drug-induced up-regulation of IL-6, IL-8 and MCP-1 and activation of NF-κB/IKBα and Stat3. Furthermore, in a xenograft mouse model, co-administration of cardamonin and the chemotherapeutic drug doxorubicin significantly retards tumor growth and simultaneously decreases CSC pools in vivo. Since cardamonin has been found in some herbs, this work suggests a potential new approach for the effective treatment of breast CSCs by administration of cardamonin either concurrent with or after chemotherapeutic drugs. |
format | Online Article Text |
id | pubmed-4808032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-48080322016-04-19 Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo Jia, Deyong Tan, Yuan Liu, Huijuan Ooi, Sarah Li, Li Wright, Kathryn Bennett, Steffany Addison, Christina L. Wang, Lisheng Oncotarget Research Paper The failure of cytotoxic chemotherapy in breast cancers has been closely associated with the presence of drug resistant cancer stem cells (CSCs). Thus, screening for small molecules that selectively inhibit growth of CSCs may offer great promise for cancer control, particularly in combination with chemotherapy. In this report, we provide the first demonstration that cardamonin, a small molecule, selectively inhibits breast CSCs that have been enriched by chemotherapeutic drugs. In addition, cardamonin also sufficiently prevents the enrichment of CSCs when simultaneously used with chemotherapeutic drugs. Specifically, cardamonin effectively abolishes chemotherapeutic drug-induced up-regulation of IL-6, IL-8 and MCP-1 and activation of NF-κB/IKBα and Stat3. Furthermore, in a xenograft mouse model, co-administration of cardamonin and the chemotherapeutic drug doxorubicin significantly retards tumor growth and simultaneously decreases CSC pools in vivo. Since cardamonin has been found in some herbs, this work suggests a potential new approach for the effective treatment of breast CSCs by administration of cardamonin either concurrent with or after chemotherapeutic drugs. Impact Journals LLC 2015-10-17 /pmc/articles/PMC4808032/ /pubmed/26506421 Text en Copyright: © 2016 Jia et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Jia, Deyong Tan, Yuan Liu, Huijuan Ooi, Sarah Li, Li Wright, Kathryn Bennett, Steffany Addison, Christina L. Wang, Lisheng Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo |
title | Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo |
title_full | Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo |
title_fullStr | Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo |
title_full_unstemmed | Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo |
title_short | Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo |
title_sort | cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808032/ https://www.ncbi.nlm.nih.gov/pubmed/26506421 |
work_keys_str_mv | AT jiadeyong cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT tanyuan cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT liuhuijuan cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT ooisarah cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT lili cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT wrightkathryn cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT bennettsteffany cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT addisonchristinal cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo AT wanglisheng cardamoninreduceschemotherapyenrichedbreastcancerstemlikecellsinvitroandinvivo |